Loading…
Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.
Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.
Earns its money from branded over-the-counter medicines, bought without a prescription, sold in volume through distributors and pharmacy chains and kept visible by heavy brand promotion. Traditional Chinese medicines make up a large part of drug sales, and eye drops and cold remedies are the best-known brands. A health-products line is being built beside the drugs.
Moat: narrow (brand, distribution). Long-established OTC brands and a nationwide sales network; little patent protection and heavy advertising reliance.
Headquarters: Nanchang, China
Size Renhe Pharmacy (000650.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.06B, the 2186th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.12 on 6 Nov 2026.
Performance Over six months the shares fell 10.0%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue fell 7.0% over the last twelve months (peer median +9.7%); the operating margin is 14.3% (peer median 7.0%).
Valuation It trades at 17.7× forward earnings against a peer median of 22.7× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.0 points above its cost of capital (7.1% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.49B | n/a | CN¥4.05B | CN¥5.00B | CN¥5.12B |
| Revenue growth | — | — | -19% | -2% | — |
| Gross profit | CN¥1.33B | n/a | CN¥1.46B | CN¥1.78B | CN¥1.78B |
| EBITDA | n/a | n/a | CN¥796M | CN¥1.09B | CN¥1.00B |
| Net income | CN¥386M | n/a | CN¥482M | CN¥567M | CN¥574M |
| Free cash flow | CN¥488M | n/a | CN¥354M | CN¥391M | CN¥1.09B |
| Capital expenditure | CN¥47.8M | n/a | CN¥286M | CN¥187M | CN¥221M |
| Total debt | CN¥2.22M | n/a | CN¥81.0M | CN¥18.5M | CN¥34.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Renhe Pharmacy 000650.SZ | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Chongqing Taiji Industry (Group) 600129.SS | $1.09B | -15% | -4% | 2% | 26.5× | n/a |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000650.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -6.0% | 9th highest of 21 |
| 6-month return | -10.0% | -16.4% | 5th highest of 20 |
| Distance from 52-week high | -20.1% | -35.1% | 3rd highest of 21 |
| Revenue growth (TTM) | -7.0% | +9.7% | 4th lowest of 19 |
| Operating margin | 14.3% | 7.0% | 4th highest of 19 |
| Forward P/E | 17.7× | 22.7× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -9.4% | 5.3% | 2nd least demanding of 13 |
| Growth delivered (Del g) | -7.0% | +4.2% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | -2.4 pp | +1.5 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +5.0 pp | -0.7 pp | 4th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |